IBRX Q1 2018 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5,000-54.5% YoY

Gross Profit

$5,000100.0% margin

Operating Income

-$28M-552200.0% margin

Net Income

-$28M-550380.0% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-58.3%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$20M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$230M

Total Liabilities

$29M

Stockholders' Equity

$200M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5,000	$11,000	-54.5%
Gross Profit	$5,000	$11,000	-54.5%
Operating Income	-$28M	-$25M	-12.3%
Net Income	-$28M	-$25M	-12.3%

Geographic Segments

San Diego California

$100,000100%